Transarterial chemoembolization is commonly performed in patients with hepatocellular carcinoma classified as Barcelona Clinic Liver Cancer staging system B or C in selected patients according to current guidelines. Transarterial chemoembolization has been shown to improve the survival of patients with unresectable hepatocellular carcinoma and Child class A and B. Transarterial chemoembolization is associated with a low rate of major complications (4–7%). Complications of transarterial chemoembolization can be categorized into injury to the liver and extrahepatic structures. Hepatocellular carcinoma with partial portal vein thrombosis is still a thorny problem, and the current treatment choices are unable to extend the survival effectively. the current study we designed to identify the preoperative factors related to the short-term a by comparing the preoperative clinical data of patients who died in the short-term (< 3 months) with those who survived after transarterial chemoembolization A total of 140 patients with hepatocellular carcinoma and partial portal vein thrombosis were enrolled in the study. A retrospective-prospective hospital-based study was conducted at Department of Tropical Medicine and Gastroenterology at Al-Rajhi University Hospitals. It was conducted in the period between 2021 and 2023. The main findings in the current study were; 1) a total of 100 (71.4%) patients were still alive up to three months following transarterial chemoembolization and 40 (28.6%) patients died, 2) non-survivors had significantly lower albumin level with higher bilirubin, aspartate transaminase and more advanced albumin/bilirubin index grade and 3)

only predictor for short-term mortality in patients underwent transarterial chemoembolization was albumin/bilirubin index grade ≥ 2 with odd's ratio was 4.11. Lastly, the current study revealed that 40 (28.6%) patients died secondary to hepatic decompensation (29/40; 72.5%) or post-embolization syndrome (11/40; 27.5%). Also, response to transarterial chemoembolization in the current study was complete, partial and stable response in 90 (64.3%), 40 (28.6%) and 10 (7.1%) patients, respectively